Michael R. Bielski Email & Phone Number

Ronkonkoma, New York, Us

DevTech Partners is a full-service technology commercialization firm with significant experience in product development, start-up company formation and management, and out-licensing campaigns. DevTech Partners works closely with physician inventors and research institutions to develop, test, patent and commercialize medical technologies via product manufacturing/sales and/or comprehensive out-licensing campaigns.Product Development: DevTech Partners directly manages the design, engineering, pre-clinical testing, patenting, regulatory, tooling, manufacturing, packaging, sterilization, marketing and sales of medical devices. The DevTech Partners team has successfully brought medical device technology from conception through clinical use and sales. The DevTech team often acts as the permanent or interim management team for start-ups formed to commercialize new technologies.Licensing: DevTech Partners works closely with inventors and research institutions to prepare for and directly manage comprehensive out-licensing campaigns. The DevTech Partners team has successfully developed licensing programs that have resulted in up-front fees, milestone payments, royalties, and collaboration agreements.

Ronkonkoma, New York, Us

Responsible for identifying, evaluating, and licensing/acquiring new medical device technologies and products that align with Dukal’s strategic goals and innovation strategy. Focus on advanced wound care and surgical devices. Develop and implement IP strategy across all Dukal product lines. Technology Identification & Business Development: Responsible for identifying medical technologies and products that solve unmet clinical needs across Dukal’s product lines. Responsible for systematically identifying and managing the outreach and business development with research institutions, universities, and clinician inventors for new medical technologies for licensing or acquisition.Due Diligence: Responsible for managing the due diligence of new opportunities that include assessments from regulatory, finance, patent, legal, product development and manufacturing teams. Due diligence results presented to Dukal leadership for go/no-go decisions. Negotiation: Responsible for developing financial models that support the ROI/IRR for new opportunities and directly negotiating the terms of the license or acquisition including options, licenses and purchase agreements. Assets licensed or acquired include patents, patent applications, know-how, data, protocols, 510ks, and tooling.IP Strategy: Responsible for developing and implementing the intellectual property strategy for Dukal, including the invention extraction and documentation of patentable subject matter, know how and trade secrets. Responsible for management of outside patent counsel.

Capseus, Inc. (formerly OsteoMedix, Inc.) was founded in 2014 to develop and commercialize a Class II medical device (BDC-15) for the collection of autograft during spinal fusion procedures. Capseus developed the BDC-15 from early conception, design, engineering, patenting and testing through FDA registration, manufacturing, packaging, sterilization, clinical use and sales.

Hairpin Technologies Inc. was founded in 2015 to expand the commercial distribution and research use of short hairpin RNA (shRNA), a versatile biomedical research and drug discovery tool invented at Cold Spring Harbor Laboratory (CSHL). As the exclusive licensing agent of CSHL, the mission of Hairpin Technologies is to negotiate and execute license agreements with manufacturers, distributors and end-users of the shRNA technology, which is protected by a robust portfolio of U.S. and international patents. In this capacity, Hairpin Technologies leads ongoing marketing, corporate outreach and out-licensing efforts to identify and engage potential licensees on behalf of CSHL.

St. Louis, Missouri, Us

Responsible for developing and implementing the intellectual property strategy for NewLeaf Symbiotics, Inc., a venture-backed agricultural biotechnology firm that has raised over $100M in financing and is commercializing a family of beneficial bacteria known as PPFMs (Pink Pigmented Facultative Methylotrophs).

Develop technology commercialization and risk-mitigation methodology for early-stage biomedical technology ventures. Advise existing early-stage life science companies on technology assessment, funding and partnership opportunities, IP strategy, licensing strategy, business planning and financial modeling. Manage teams that develop technology commercialization strategies for start-up life science companies. Assess early-stage technologies for licensing and commercialization potential. Member of the Bioscience Screening Committee for the Long Island Angel Network. Prepare early-stage life science companies to present to the Long Island Angel Network.

Central Islip, Ny, Us

Course Instructor for Selected Topics in Corporate Law: Garage to IPO.

Stony Brook, Ny, Us

Deliver technology commercialization courses to MBA students at SUNY Stony Brook. Manage student/client interactions for Industry Project (MBA 521). Invited Guest Lecturer, Technological Innovations Course, SUNY College of Business, 2008-2013.

Williston, Vermont, Us

Conducted technical and IP due diligence for over $150 million in venture capital investments across multiple technologies including biomedical, security, consumer products and alternative energy. Developed and implemented IP strategies for Fortune 500 and start-up clients which included directed innovation, invention extraction and documentation processes. Identified and valued early stage technologies and IP for subsequent licensing/acquisition negotiations. Developed commercialization strategies and participated in patent licensing/acquisition negotiations. Conducted competitive patent analytics to identify IP strengths, weaknesses, opportunities and threats.

J.D., Intellectual Property, Technology Transfer And Commercialization

M.S., Neuroscience

Molecular Biology

B.S., Biology